Biotechnology News

Total Revenue Increased 22% to $77.5 Million, with MACI Revenue Growth of 23% Net Income of $2.2 Million and Free Cash Flow of $14.3 Million Full-Year 2026 Revenue Guidance Raised to $330 to $340...

NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and...

Dosing underway in Phase 2a multidose portion of the INLIGHTTM trial of WVE-007 (INHBE GalNAc-siRNA) in individuals with obesity (BMI: 35-50 kg/m2) and comorbidities; trial will also inform WVE-007's...

STAT3 acts as a convergent node downstream of multiple signaling pathways implicated in ulcerative colitis (UC), integrating immune dysregulation, inflammation and tissue remodeling  More than 70% of...

PharmAla files Q3 financial statements, highlighting improved financial performance compared to 2025, and provides an update on motions passed at their AGM

Highlights FDA End-of-Phase 2 (EOP2) meeting minutes confirmed a registrational pathway for ATH434 in Multiple System Atrophy (MSA)FDA agreed that a single pivotal Phase 3 trial plus confirmatory...

– COMO and CAPRI trials together rapidly enrolled over 480 participants in five months, demonstrating continued enthusiasm for DURAVYU trial participation among retinal specialists and patients ––  –...

Immunocore to report second quarter 2026 financial results and host call on August 6, 2026 (OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 30 July 2026) Immunocore Holdings plc...

Partnership with Cure HHT strengthens patient engagement and supports streamlined clinical trial executionHarmony-HHT Phase 1/2 trial activates first clinical site at Massachusetts General Hospital,...

Global Experts in MSC Clinical Translation to Advise Ebstrocel™ Regulatory and Clinical Development and Guide Expansion of CORDStrom Product Opportunities BOCA RATON, Fla., July 30, 2026 (GLOBE...